Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $109.58, for a total value of $2,191,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $84,133,332.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00.
- On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00.
- On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.24, for a total transaction of $2,144,800.00.
- On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00.
Halozyme Therapeutics Stock Performance
Shares of HALO stock opened at $109.84 on Friday. The company has a market capitalization of $12.47 billion, a price-to-earnings ratio of 32.79, a PEG ratio of 0.42 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a 50-day simple moving average of $105.64 and a 200 day simple moving average of $82.86. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $116.85.
Analyst Upgrades and Downgrades
HALO has been the subject of a number of research reports. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Citizens Jmp boosted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $94.00.
View Our Latest Report on Halozyme Therapeutics
Institutional Investors Weigh In On Halozyme Therapeutics
A number of large investors have recently bought and sold shares of the company. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the second quarter valued at approximately $214,504,000. William Blair Investment Management LLC acquired a new position in Halozyme Therapeutics during the second quarter valued at approximately $196,540,000. Jupiter Topco LLC bought a new stake in Halozyme Therapeutics during the second quarter worth $105,570,000. Caisse de depot et placement du Quebec bought a new stake in Halozyme Therapeutics during the second quarter worth $83,940,000. Finally, Congress Asset Management Co. boosted its holdings in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Key Halozyme Therapeutics News
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: A Dutch patent court found Merck’s subcutaneous Keytruda infringed a Halozyme patent and ordered MSD to stop manufacturing, selling, importing, or stocking the product in eight European markets: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The ruling could protect Halozyme’s intellectual-property position and potential royalty economics. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck’s Keytruda SC in Multiple European Markets
- Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to cover two additional exclusive targets, bringing the total to eight. The agreement increases the opportunity for future development milestones and royalties and supports Halozyme’s recurring revenue growth. HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
- Neutral Sentiment: The Keytruda decision is a significant win, but the ongoing patent dispute, possible appeals, and the timing of any commercial impact create uncertainty around how quickly the ruling will translate into financial results.
- Negative Sentiment: JPMorgan raised its HALO price target from $70 to $78 but maintained a “neutral” rating. The new target implies roughly 29% downside from the referenced $109.84 price, signaling concern that the stock’s valuation already reflects much of its growth and legal upside. JPMorgan Raises Halozyme Price Target
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.
Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
